

Robert G Gish

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/625151/robert-g-gish-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

267
papers

12,441
citations

60
h-index

105
g-index

328
ext. papers

14,210
ext. citations

5.6
avg, IF

6.17
L-index

#	Paper	IF	Citations
267	Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science.. <i>Journal of Clinical and Translational Hepatology</i> , 2022 , 10, 374-382	5.2	1
266	Letter to the editor.. <i>Hepatology</i> , 2022 ,	11.2	
265	Letter to the Editor: Importance of Universal Screening for Chronic Hepatitis B Infection in Adults in the United States.. <i>Hepatology</i> , 2021 ,	11.2	0
264	Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment. <i>Gut</i> , 2021 ,	19.2	7
263	An Updated Assessment of Chronic Hepatitis B Prevalence Among Foreign-Born Persons Living in the United States. <i>Hepatology</i> , 2021 , 74, 607-626	11.2	20
262	Epidemiology and Prevention of Tuberculosis and Chronic Hepatitis B Virus Infection in the United States. <i>Journal of Immigrant and Minority Health</i> , 2021 , 23, 1267-1279	2.2	2
261	Assessment of treatment options for patients with hepatitis C virus recombinant form 2k/1b. <i>Hepatology Research</i> , 2021 , 51, 156-165	5.1	0
260	Low Prevalence of Vaccination or Documented Immunity to Hepatitis A and Hepatitis B Viruses Among Individuals with Chronic Liver Disease. <i>American Journal of Medicine</i> , 2021 , 134, 882-892	2.4	1
259	Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 743-753	18.8	14
258	Autoimmune Hepatitis in Cuban Patients: A Retrospective Analysis of Clinical and Histological Profiles, Treatments, and Outcomes. <i>Current Therapeutic Research</i> , 2020 , 93, 100594	2.4	
257	Hepatitis B virus diagnostics: anything new? 2020 , 220-230		0
256	Geographic regions with high prevalence of nonalcoholic steatohepatitis-related hepatic fibrosis are also observed to demonstrate high prevalence of metabolic disease risk factors and low consumption of fruits and vegetables. <i>Clinical Nutrition Experimental</i> , 2020 , 30, 15-26	2	1
255	Hepatitis B Core Antibody: Role in Clinical Practice in 2020. <i>Current Hepatology Reports</i> , 2020 , 19, 254-265		1
254	Normal alkaline phosphatase levels are dependent on race/ethnicity: NationalGEP Health and Nutrition Examination Survey data. <i>BMJ Open Gastroenterology</i> , 2020 , 7,	3.9	4
253	1066. Immune Escape Mutant Detection Using Commercially Available Methods for Hepatitis B Surface Antigen Serological Testing. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S562-S562	1	
252	RNA Interference Therapy With ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection. <i>Hepatology</i> , 2020 , 72, 19-31	11.2	47
251	We Are All Africans: A Highly Personal Migratory View of the History of Hepatitis B. <i>Clinical Liver Disease</i> , 2020 , 16, 24-33	2.2	1

250	Point of Care Diagnostic Testing for Hepatitis B Virus. <i>Current Hepatology Reports</i> , 2020 , 19, 245-253	1	2
249	Prevalence of Chronic Hepatitis B Virus Infection in the United States. <i>American Journal of Gastroenterology</i> , 2020 , 115, 1429-1438	0.7	32
248	Changing incidence of reported viral hepatitis in China from 2004 to 2016: an observational study. <i>BMJ Open</i> , 2019 , 9, e028248	3	8
247	PS-080-Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg Journal of Hepatology, 2019 , 70, e51-e52	13.4	24
246	Practical strategies for pruritus management in the obeticholic acid-treated patient with PBC: proceedings from the 2018 expert panel. <i>BMJ Open Gastroenterology</i> , 2019 , 6, e000256	3.9	7
245	Increasing metabolic co-morbidities are associated with higher risk of advanced fibrosis in nonalcoholic steatohepatitis. <i>PLoS ONE</i> , 2019 , 14, e0220612	3.7	9
244	Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Patients with Hematological and Solid Tumor Malignancies. <i>Clinics in Liver Disease</i> , 2019 , 23, 511-519	4.6	1
243	Global Perspective on Hepatitis B Virus Infections in the Era of Effective Vaccines. <i>Clinics in Liver Disease</i> , 2019 , 23, 383-399	4.6	16
242	Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Introduction and Immunology. <i>Clinics in Liver Disease</i> , 2019 , 23, 487-492	4.6	2
241	Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Transplant Recipients. <i>Clinics in Liver Disease</i> , 2019 , 23, 493-509	4.6	2
240	Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Other Populations and Newer Agents. <i>Clinics in Liver Disease</i> , 2019 , 23, 521-534	4.6	1
239	PS-052-End of study results from LIMT HDV study: 36% durable virologic response at 24 weeks post-treatment with pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infection. <i>Journal of Hepatology</i> , 2019 , 70, e32	13.4	24
238	More Severe Deficits in Performance Status at Time of Liver Transplant is Associated With Significantly Higher Risk of Death Following Liver Transplantation. <i>Journal of Clinical Gastroenterology</i> , 2019 , 53, e392-e399	3	7
237	Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. <i>Journal of Hepatology</i> , 2019 , 70, 1008-1015	13.4	40
236	Improved liver transplant waitlist mortality and lower risk of disease progression among chronic hepatitis C patients awaiting liver transplantation after the introduction of direct-acting antiviral therapies in the United States. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 350-361	3.4	9
235	Increasing metabolic co-morbidities are associated with higher risk of advanced fibrosis in nonalcoholic steatohepatitis 2019 , 14, e0220612		
234	Increasing metabolic co-morbidities are associated with higher risk of advanced fibrosis in nonalcoholic steatohepatitis 2019 , 14, e0220612		
233	Increasing metabolic co-morbidities are associated with higher risk of advanced fibrosis in nonalcoholic steatohepatitis 2019 , 14, e0220612		

232	Increasing metabolic co-morbidities are associated with higher risk of advanced fibrosis in nonalcoholic steatohepatitis 2019 , 14, e0220612		
231	Identification of recombinant strains in HCV genotype 1 and 3: Is it needed?. <i>Liver International</i> , 2018 , 38, 958	7.9	1
230	Significant Hepatic Fibrosis Among Treatment-Naive Chronic Hepatitis B Virus With Increased Hepatitis B Virus DNA and Normal Alanine Aminotransferase. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 146-148	6.9	0
229	A research agenda for curing chronic hepatitis B virus infection. <i>Hepatology</i> , 2018 , 67, 1127-1131	11.2	51
228	Global HBV burden: guesstimates and facts. <i>Hepatology International</i> , 2018 , 12, 315-329	8.8	37
227	Entecavir versus other oral antiviral drugs for chronic hepatitis B. <i>The Cochrane Library</i> , 2018 ,	5.2	78
226	Diagnostics of Hepatitis B Virus: Standard of Care and Investigational. <i>Clinical Liver Disease</i> , 2018 , 12, 5-11	2.2	10
225	Epidemiology and Natural History of Chronic Hepatitis B Virus Infection 2018 , 63-89		3
224	Identification of hepatitis C virus 2k/1b intergenotypic recombinants in Georgia. <i>Liver International</i> , 2018 , 38, 451-457	7.9	12
223	Management of hepatitis C virus infection in the Asia-Pacific region: an update. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 52-62	18.8	43
222	Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection. <i>Expert Review of Clinical Pharmacology</i> , 2017 , 10, 707-716	3.8	21
221	Prolonged RNA interference therapy with ARC-520 Injection in treatment naïve, HBeAg positive and negative patients with chronic HBV results in significant reductions of HBs antigen. <i>Journal of Hepatology</i> , 2017 , 66, S27	13.4	16
220	RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	216
219	Clinical characteristics of antimitochondrial antibody-positive patients at a safety net health care system in Arizona. <i>BMJ Open Gastroenterology</i> , 2017 , 4, e000158	3.9	3
218	A phase 1 study to evaluate safety and tolerability of escalating single doses of the hepatitis B virus RNA interference drug ARC-521 in a healthy volunteer population. <i>Journal of Hepatology</i> , 2017 , 66, S265-268	13.4	5
217	Diversity of clinical presentation and virological characteristics of hepatitis delta in different regions world-wide: results of the Hepatitis Delta International network. <i>Journal of Hepatology</i> , 2017 , 66, S257-S258	13.4	2
216	Markov modeling in hepatitis B screening and linkage to care. <i>Theoretical Biology and Medical Modelling</i> , 2017 , 14, 11	2.3	6
215	Drugs in Development for Hepatitis B. <i>Drugs</i> , 2017 , 77, 1263-1280	12.1	21

214	Safety, Tolerability, and Pharmacokinetics of ARC-520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers. <i>Clinical Pharmacology in Drug Development</i> , 2017 , 6, 350-362	2.3	58
213	Community-based real-world treatment outcomes of sofosbuvir/ledipasvir in Asians with chronic hepatitis C virus genotype 6 in the United States. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 17-21	3.4	12
212	Hepatitis B surface antigen loss and sustained viral suppression in Asian chronic hepatitis B patients: A community-based real-world study. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 1089-1097	3.4	11
211	HBV/HCV Coinfection and Possible Reactivation of HBV Following DAA Use. <i>Gastroenterology and Hepatology</i> , 2017 , 13, 292-295	0.7	1
210	Successful Domino Liver Transplantation from a Patient with Methylmalonic Acidemia. <i>JIMD Reports</i> , 2016 , 25, 87-94	1.9	19
209	Chronic Hepatitis B Viral Infection 2016 , 387-391		
208	Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma. <i>Liver Transplantation</i> , 2016 , 22, 1356-66	4.5	19
207	Predicting HBsAg Clearance Responses during ARC-520 RNA Interference (RNAi) Therapy Based on HBsAg Epitope Profile Analysis. <i>Journal of Hepatology</i> , 2016 , 64, S602	13.4	3
206	Defining the possibilities: is short duration treatment of chronic hepatitis C genotype 1 with sofosbuvir-containing regimens likely to be as effective as current regimens?. <i>Expert Review of Anti-Infective Therapy</i> , 2016 , 14, 41-56	5.5	4
205	Hepatitis C virus as a systemic disease: reaching beyond the liver. <i>Hepatology International</i> , 2016 , 10, 415-23	8.8	95
204	Chronic hepatitis B virus in the Philippines. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016 , 31, 945-52	4	6
203	Views of US Voters on Compensating Living Kidney Donors. <i>JAMA Surgery</i> , 2016 , 151, 710-6	5.4	11
202	Birth cohort-specific disparities in hepatocellular carcinoma stage at diagnosis, treatment, and long-term survival. <i>Journal of Hepatology</i> , 2016 , 64, 326-332	13.4	17
201	Metabolic Manifestations and Complications Associated With Chronic Hepatitis C Virus Infection. <i>Gastroenterology and Hepatology</i> , 2016 , 12, 293-9	0.7	12
200	Evolving New Strategies for the Medical Management of Chronic Hepatitis B Virus Infection. <i>Gastroenterology and Hepatology</i> , 2016 , 12, 679-689	0.7	1
199	Surgical Treatment of Hepatocellular Carcinoma: Resection Versus Transplantation. <i>Difficult Decisions in Surgery: an Evidence-based Approach</i> , 2016 , 73-84	0	2
198	Race/ethnicity-specific disparities in cancer incidence, burden of disease, and overall survival among patients with hepatocellular carcinoma in the United States. <i>Cancer</i> , 2016 , 122, 2512-23	6.4	62
197	Future Therapy for Hepatitis B Virus: Role of Immunomodulators. <i>Current Hepatology Reports</i> , 2016 , 15, 237-244	1	20

196	Alcoholic Liver Disease: High Risk or Low Risk for Developing Hepatocellular Carcinoma?. <i>Clinics in Liver Disease</i> , 2016 , 20, 563-80	4.6	40
195	Is response guided therapy dead? Low cure rates in patients with detectable hepatitis C virus at week 4 of treatment. <i>Hepatology International</i> , 2016 , 10, 624-31	8.8	11
194	Differential Reductions in Viral Antigens Expressed from CCCDNAs Integrated DNA in Treatment Naïve HBEAG Positive and Negative Patients with Chronic HBV after RNA Interference Therapy with ARC-520. <i>Journal of Hepatology</i> , 2016 , 64, S390-S391	13.4	18
193	Sofosbuvir/Ledipasvir without Ribavirin in the Treatment of Asians with Chronic Hepatitis C Virus Genotype 6 in the United States: Community-Based Real World Outcomes. <i>Journal of Hepatology</i> , 2016 , 64, S815-S816	13.4	4
192	Treatment of Chronically HBV-Infected Chimpanzees with RNA Interference Therapeutic ARC-520 LED to Potent Reduction of Viral MRNA, DNA and Proteins without Observed Drug Resistance. <i>Journal of Hepatology</i> , 2016 , 64, S398	13.4	10
191	Direct-acting antivirals for the treatment of chronic hepatitis C in patients with chronic kidney disease. <i>Therapeutic Advances in Gastroenterology</i> , 2016 , 9, 887-897	4.7	11
190	Elevated alpha-fetoprotein: differential diagnosis - hepatocellular carcinoma and other disorders. <i>Clinics in Liver Disease</i> , 2015 , 19, 309-23	4.6	73
189	Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent. <i>Antiviral Research</i> , 2015 , 121, 97-108	10.8	105
188	Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities. <i>Antiviral Research</i> , 2015 , 121, 47-58	10.8	175
187	Changing Nomenclature for PBC: From Cirrhosis To Cholangitis. <i>American Journal of Gastroenterology</i> , 2015 , 110, 1536-8	0.7	26
186	Changing nomenclature for PBC: From Cirrhosis To Cholangitis. <i>Digestive and Liver Disease</i> , 2015 , 47, 924-6	3.3	14
185	Changing nomenclature for PBC: From Cirrhosis To Cholangitis. <i>Gastroenterology</i> , 2015 , 149, 1627-9	13.3	56
184	Changing Nomenclature for PBC: From Cirrhosis To Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 1867-9	6.9	14
183	Changing nomenclature for PBC: From Cirrhosis To Cholangitis. <i>Journal of Hepatology</i> , 2015 , 63, 1285-7	13.4	55
182	Changing nomenclature for PBC: from Cirrhosis To Cholangitis. <i>Gut</i> , 2015 , 64, 1671-2	19.2	22
181	American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. <i>Gastroenterology</i> , 2015 , 148, 221-244.e3	13.3	335
180	Portal vein thrombosis. <i>Clinics in Liver Disease</i> , 2015 , 19, 199-221	4.6	26
179	Medical interventions associated with HBV reactivation: Common and less common. <i>Clinical Liver Disease</i> , 2015 , 5, 32-34	2.2	3

178	United Network for Organ Sharing regional variations in appeal denial rates with non-standard Model for End-Stage Liver Disease/Pediatric End-Stage Liver Disease exceptions: support for a national review board. <i>Clinical Transplantation</i> , 2015 , 29, 513-22	3.8	13
177	Comparable efficacy with entecavir monotherapy and tenofovir-entecavir combination in chronic hepatitis B patients. <i>BMJ Open Gastroenterology</i> , 2015 , 2, e000030	3.9	2
176	Changing nomenclature for PBC: From RirrhosisPto RholangitisP <i>Hepatology</i> , 2015 , 62, 1620-2	11.2	92
175	The impact of pretransplant hepatic encephalopathy on survival following liver transplantation. <i>Liver Transplantation</i> , 2015 , 21, 873-80	4.5	24
174	Predictors of hepatic decompensation after TACE for hepatocellular carcinoma. <i>BMJ Open Gastroenterology</i> , 2015 , 2, e000032	3.9	18
173	Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine. <i>World Journal of Gastroenterology</i> , 2015 , 21, 4644-51	5.6	18
172	Changing nomenclature for PBC: From RirrhosisPto RholangitisP <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015 , 39, e57-9	2.4	29
171	High rate of core promoter and precore mutations in patients with chronic hepatitis B. <i>Hepatology International</i> , 2015 , 9, 209-17	8.8	7
170	The Effector Domain of MARCKS Is a Nuclear Localization Signal that Regulates Cellular PIP2 Levels and Nuclear PIP2 Localization. <i>PLoS ONE</i> , 2015 , 10, e0140870	3.7	19
169	Hepatocellular Carcinoma: Current Questions and Future Directions. <i>Gastroenterology and Hepatology</i> , 2015 , 11, 182-5	0.7	2
168	Hepatitis delta: epidemiology, diagnosis and management 36 years after discovery. <i>Current Gastroenterology Reports</i> , 2014 , 16, 365	5	71
167	Inhibition of Hec1 as a novel approach for treatment of primary liver cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 74, 511-20	3.5	15
166	Immunosuppression in Patients with Chronic Hepatitis B. <i>Current Hepatology Reports</i> , 2014 , 13, 235-244	1	38
165	Hepatitis C virus triggers mitochondrial fission and attenuates apoptosis to promote viral persistence. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 6413-8	11.5	164
164	Hepatocellular carcinoma surveillance: a national survey of current practices in the USA. <i>Digestive Diseases and Sciences</i> , 2014 , 59, 3073-7	4	19
163	Hepatic encephalopathy is associated with significantly increased mortality among patients awaiting liver transplantation. <i>Liver Transplantation</i> , 2014 , 20, 1454-61	4.5	30
162	Current treatment guidelines for chronic hepatitis B and their applications. <i>Journal of Clinical Gastroenterology</i> , 2014 , 48, 773-83	3	11
161	A simple and inexpensive point-of-care test for hepatitis B surface antigen detection: serological and molecular evaluation. <i>Journal of Viral Hepatitis</i> , 2014 , 21, 905-8	3.4	23

160	Hepatitis D Virus: A Call to Screening. <i>Gastroenterology and Hepatology</i> , 2014 , 10, 647-86	0.7	2
159	Chronic hepatitis B: what should be the goal for new therapies?. <i>Antiviral Research</i> , 2013 , 98, 27-34	10.8	95
158	One-step real-time PCR assay for detection and quantitation of hepatitis D virus RNA. <i>Journal of Virological Methods</i> , 2013 , 193, 531-5	2.6	24
157	Cellular mechanics of germ band retraction in <i>Drosophila</i> . <i>Developmental Biology</i> , 2013 , 384, 205-13	3.1	19
156	Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. <i>Hepatology</i> , 2013 , 57, 881-9	11.2	159
155	Investigation and diagnostic pathways 2013 , 48-64		
154	Coinfection with hepatitis B and D: epidemiology, prevalence and disease in patients in Northern California. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013 , 28, 1521-5	4	69
153	Society of Interventional Radiology critique and commentary on the Cochrane report on transarterial chemoembolization. <i>Hepatology</i> , 2013 , 57, 1675-6	11.2	8
152	Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive nucleoside-naive patients treated with entecavir. <i>Antiviral Therapy</i> , 2013 , 18, 691-8	1.6	15
151	Chronic HBV infection outside treatment guidelines: is treatment needed?. <i>Antiviral Therapy</i> , 2013 , 18, 229-35	1.6	13
150	Sodium benzoate for treatment of hepatic encephalopathy. <i>Gastroenterology and Hepatology</i> , 2013 , 9, 219-27	0.7	20
149	Delta virus infection: epidemiology and initiatives to intercept it. <i>Gastroenterology and Hepatology</i> , 2013 , 9, 589-91	0.7	
148	Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma. <i>Gastroenterology and Hepatology</i> , 2013 , 9, 1-24	0.7	5
147	Efficacy of combination treatment modalities for intermediate and advanced hepatocellular carcinoma: intra-arterial therapies, sorafenib and novel small molecules. <i>Translational Cancer Research</i> , 2013 , 2, 460-471	0.3	7
146	Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma. <i>Clinical Advances in Hematology and Oncology</i> , 2013 , 11 Suppl 5, 1-22; quiz 2 p following p22	0.6	1
145	HCV In At Risk Populations: Who Can be Treated and How?. <i>Current Hepatitis Reports</i> , 2012 , 11, 1-9		
144	Selection of chronic hepatitis B therapy with high barrier to resistance. <i>Lancet Infectious Diseases</i> , 2012 , 12, 341-53	25.5	111
143	Chronic hepatitis B infection. <i>Clinics in Liver Disease</i> , 2012 , 16, 347-69	4.6	44

142	Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2012 , 10, 941-6; quiz e68	6.9	74
141	Liver disease in Viet Nam: screening, surveillance, management and education: a 5-year plan and call to action. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012 , 27, 238-47	4	25
140	Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012 , 6, 173-85	4.2	51
139	Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73. <i>Cancer Biomarkers</i> , 2012 , 11, 161-71	3.8	38
138	The impact of race/ethnicity on the clinical epidemiology of autoimmune hepatitis. <i>Journal of Clinical Gastroenterology</i> , 2012 , 46, 155-61	3	46
137	Acute liver failure in adults: an evidence-based management protocol for clinicians. <i>Gastroenterology and Hepatology</i> , 2012 , 8, 161-212	0.7	6
136	Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications. <i>World Journal of Gastroenterology</i> , 2012 , 18, 498-506	5.6	45
135	The NS5A replication complex inhibitors: difference makers?. <i>Clinics in Liver Disease</i> , 2011 , 15, 627-39	4.6	28
134	Hepatocellular carcinoma: molecular and genomic guideline for the clinician. <i>Clinics in Liver Disease</i> , 2011 , 15, 307-21, vii-x	4.6	15
133	A clinical assessment of Wilson disease in patients with concurrent liver disease. <i>Journal of Clinical Gastroenterology</i> , 2011 , 45, 267-73	3	14
132	Clinical management and case reports for the treatment of hepatocellular carcinoma with sorafenib. <i>Journal of Clinical Gastroenterology</i> , 2011 , 45, 733-7	3	3
131	RNA interference and its potential applications to chronic HBV treatment: results of a Phase I safety and tolerability study. <i>Antiviral Therapy</i> , 2011 , 16, 547-54	1.6	17
130	Clinical outcomes of liver transplantation for HBV-related hepatocellular carcinoma: data from the NIH HBV OLT study. <i>Clinical Transplantation</i> , 2011 , 25, E152-62	3.8	12
129	Hepatitis B in the Greater San Francisco Bay Area: an integrated programme to respond to a diverse local epidemic. <i>Journal of Viral Hepatitis</i> , 2011 , 18, e40-51	3.4	19
128	Is chronic hepatitis B being undertreated in the United States?. <i>Journal of Viral Hepatitis</i> , 2011 , 18, 377-83	3.4	126
127	Development of hepatocellular carcinoma in autoimmune hepatitis patients: a case series. <i>Digestive Diseases and Sciences</i> , 2011 , 56, 578-85	4	51
126	Reliability and predictive validity of a hepatitis-related symptom inventory in HIV-infected individuals referred for Hepatitis C treatment. <i>AIDS Research and Therapy</i> , 2011 , 8, 29	3	3
125	Hepatocellular carcinoma: locoregional and targeted therapies. <i>Gastroenterology Clinics of North America</i> , 2011 , 40, 599-610	4.4	6

124	Novel changes in glycosylation of serum Apo-J in patients with hepatocellular carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 1222-9	4	33
123	Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2010 , 17, 16-22	3.4	109
122	1007 RISK OF RENAL TOXICITY WITH TENOFOVIR DF (TDF) FOR CHRONIC HEPATITIS B (CHB). <i>Journal of Hepatology</i> , 2010 , 52, S388-S389	13.4	5
121	Safety and efficacy of viremide versus ribavirin in ViSER2: randomized, double-blind study in therapy-naïve hepatitis C patients. <i>Journal of Hepatology</i> , 2010 , 52, 32-8	13.4	36
120	A multidisciplinary approach to the management of hepatocellular carcinoma. <i>Gastroenterology and Hepatology</i> , 2010 , 6, 1-16	0.7	7
119	Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma. <i>Gastroenterology and Hepatology</i> , 2010 , 6, 1-16	0.7	
118	Clinical roundtable monograph. Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma. <i>Clinical Advances in Hematology and Oncology</i> , 2010 , 8, 2 p preceding 4-15	0.6	1
117	To "be" or not to "be": that is the question. <i>American Journal of Gastroenterology</i> , 2009 , 104, 1948-52	0.7	17
116	A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma. <i>Hepatology International</i> , 2009 , 3, 480-9	8.8	18
115	The new epidemiology of hepatitis B in the United States. <i>Current Hepatitis Reports</i> , 2009 , 8, 3-9		
114	Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2009 , 16, 784-9	3.4	13
113	Duplication of MER115 on chromosome 4 in patients with primary biliary cirrhosis. <i>Liver International</i> , 2009 , 29, 375-83	7.9	7
112	Hepatitis B treatment: Current best practices, avoiding resistance. <i>Cleveland Clinic Journal of Medicine</i> , 2009 , 76 Suppl 3, S14-9	2.8	13
111	Monotherapy vs multiple-drug therapy: the experts debate. <i>Cleveland Clinic Journal of Medicine</i> , 2009 , 76 Suppl 3, S20-4	2.8	1
110	The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. <i>Value in Health</i> , 2008 , 11, 527-38	3.3	100
109	Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2008 , 27, 1240-52	6.1	23
108	Diagnosis of chronic hepatitis B and the implications of viral variants and mutations. <i>American Journal of Medicine</i> , 2008 , 121, S12-21	2.4	1
107	The degree of readiness of selected biomarkers for the early detection of hepatocellular carcinoma: notes from a recent workshop. <i>Cancer Biomarkers</i> , 2008 , 4, 19-33	3.8	35

106	Hepatocellular carcinoma (HCC): current and evolving therapies. <i>IDrugs: the Investigational Drugs Journal</i> , 2008 , 11, 198-203		9
105	Medical therapies to extend survival in hepatocellular carcinoma. <i>Clinical Advances in Hematology and Oncology</i> , 2008 , 6, 1-14; quiz 15	0.6	1
104	Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2007 , 5, 799-802	6.9	69
103	Genotyping and genomic sequencing in clinical practice. <i>Clinics in Liver Disease</i> , 2007 , 11, 761-95, viii	4.6	11
102	Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. <i>Gastroenterology</i> , 2007 , 133, 1437-44	13.3	283
101	Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. <i>Hepatology</i> , 2007 , 45, 569-78	11.2	88
100	Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. <i>Hepatology</i> , 2007 , 46, 324-9	11.2	166
99	Efficacy of interferon alpha-2b induction therapy before retreatment for chronic hepatitis C. <i>Liver International</i> , 2007 , 27, 1111-8	7.9	10
98	Prevalence of hepatic iron overload and association with hepatocellular cancer in end-stage liver disease: results from the National Hemochromatosis Transplant Registry. <i>Liver International</i> , 2007 , 27, 1394-401	7.9	63
97	Improving outcomes for patients with chronic hepatitis B. <i>Current Gastroenterology Reports</i> , 2007 , 9, 14-22	5	14
96	Improving clinical trial design for hepatocellular carcinoma treatments. <i>Oncology Reviews</i> , 2007 , 1, 45-52.	4.3	1
95	A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B. <i>American Journal of Gastroenterology</i> , 2007 , 102, 2718-23	0.7	43
94	Customizing the management of chronic hepatitis B virus infection. <i>Seminars in Liver Disease</i> , 2007 , 27 Suppl 1, 9-17	7.3	8
93	Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3069-75	2.2	202
92	Virological response and safety outcomes in therapy-naïve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study. <i>Journal of Hepatology</i> , 2007 , 47, 51-9	13.4	41
91	Improving outcomes for patients with chronic hepatitis B. <i>Hepatology Research</i> , 2007 , 37, S67-78	5.1	4
90	Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. <i>Pharmacoeconomics</i> , 2007 , 25, 963-77	4.4	34
89	Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. <i>Hepatology</i> , 2006 , 44, 915-24	11.2	231

88	Hepatitis B in liver transplant recipients. <i>Liver Transplantation</i> , 2006 , 12, S54-64	4.5	18
87	Model for end-stage liver disease (MELD) exception guidelines. <i>Liver Transplantation</i> , 2006 , 12, S85-7	4.5	48
86	Model for end-stage liver disease (MELD) exception for familial amyloidotic polyneuropathy. <i>Liver Transplantation</i> , 2006 , 12, S100-1	4.5	1
85	Model for end-stage liver disease (MELD) exception for ascites. <i>Liver Transplantation</i> , 2006 , 12, S88-90	4.5	7
84	Model for end-stage liver disease (MELD) exception for Budd-Chiari syndrome. <i>Liver Transplantation</i> , 2006 , 12, S93-4	4.5	7
83	Model for end-stage liver disease (MELD) exception for cholangiocarcinoma or biliary dysplasia. <i>Liver Transplantation</i> , 2006 , 12, S95-7	4.5	66
82	Model for end-stage liver disease (MELD) exception for bacterial cholangitis. <i>Liver Transplantation</i> , 2006 , 12, S91-2	4.5	17
81	Model for end-stage liver disease (MELD) exception for cystic fibrosis. <i>Liver Transplantation</i> , 2006 , 12, S98-9	4.5	10
80	Model for end-stage liver disease (MELD) exception for hepatic encephalopathy. <i>Liver Transplantation</i> , 2006 , 12, S102-4	4.5	10
79	Model for end-stage liver disease (MELD) exception for portal hypertensive gastrointestinal bleeding. <i>Liver Transplantation</i> , 2006 , 12, S112-3	4.5	4
78	Model for end-stage liver disease (MELD) exception for uncommon hepatic tumors. <i>Liver Transplantation</i> , 2006 , 12, S122-3	4.5	4
77	Model for end-stage liver disease (MELD) exception for hepatopulmonary syndrome. <i>Liver Transplantation</i> , 2006 , 12, S105-7	4.5	68
76	Model for end-stage liver disease (MELD) exception for primary hyperoxaluria. <i>Liver Transplantation</i> , 2006 , 12, S117-8	4.5	5
75	Model for end-stage liver disease (MELD) exception for unusual metabolic liver diseases. <i>Liver Transplantation</i> , 2006 , 12, S124-7	4.5	7
74	Model for end-stage liver disease (MELD) exception for polycystic liver disease. <i>Liver Transplantation</i> , 2006 , 12, S110-1	4.5	37
73	Model for end-stage liver disease (MELD) exception for portopulmonary hypertension. <i>Liver Transplantation</i> , 2006 , 12, S114-6	4.5	60
72	Model for end-stage liver disease (MELD) exception for severe pruritus. <i>Liver Transplantation</i> , 2006 , 12, S119	4.5	3
71	Model for end-stage liver disease (MELD) exception small-for-size syndrome. <i>Liver Transplantation</i> , 2006 , 12, S120-1	4.5	3

70	Model for end-stage liver disease (MELD) exception for hereditary hemorrhagic telangiectasia. <i>Liver Transplantation</i> , 2006 , 12, S108-9	4.5	14
69	Model for end-stage liver disease (MELD) exception guidelines: results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula. <i>Liver Transplantation</i> , 2006 , 12, S128-36	4.5	131
68	Molecular epidemiology of hepatitis C virus subtype 3a in injecting drug users. <i>Journal of Medical Virology</i> , 2006 , 78, 1296-303	19.7	50
67	T1653 mutation in the box alpha increases the risk of hepatocellular carcinoma in patients with chronic hepatitis B virus genotype C infection. <i>Clinical Infectious Diseases</i> , 2006 , 42, 1-7	11.6	70
66	Treating HCV with ribavirin analogues and ribavirin-like molecules. <i>Journal of Antimicrobial Chemotherapy</i> , 2006 , 57, 8-13	5.1	82
65	A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. <i>New England Journal of Medicine</i> , 2006 , 354, 1001-10	59.2	1146
64	Hepatocellular carcinoma: overcoming challenges in disease management. <i>Clinical Gastroenterology and Hepatology</i> , 2006 , 4, 252-61	6.9	48
63	Chronic hepatitis B: current testing strategies. <i>Clinical Gastroenterology and Hepatology</i> , 2006 , 4, 666-766.9	6.9	48
62	Chronic hepatitis B: a critical appraisal of current approaches to therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2006 , 4, 233-48	6.9	26
61	Entecavir. <i>Drugs</i> , 2006 , 66, 1623-1624	12.1	
60	Risk Factors and Treatment for Hepatocellular Carcinoma. <i>Gastroenterology and Hepatology</i> , 2006 , 2, 477-478	0.7	1
59	Current developments in the treatment of hepatitis and hepatobiliary disease. <i>Clinical Advances in Hematology and Oncology</i> , 2006 , 4, 511-2	0.6	
58	Future Therapies for Hepatitis C. <i>Antiviral Therapy</i> , 2006 , 11, 397-408	1.6	21
57	Management of hepatitis C virus in special populations: patient and treatment considerations. <i>Clinical Gastroenterology and Hepatology</i> , 2005 , 3, 311-8	6.9	27
56	Current treatment and future directions in the management of chronic hepatitis B viral infection. <i>Clinics in Liver Disease</i> , 2005 , 9, 541-65, v	4.6	20
55	Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry. <i>Gastroenterology</i> , 2005 , 129, 494-503	13.3	93
54	Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. <i>Journal of Infectious Diseases</i> , 2005 , 191, 825-9	7	186
53	Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. <i>Journal of Hepatology</i> , 2005 , 43, 60-6	13.4	79

52	Survival After Liver Transplantation in Patients With Hepatic Iron Overload: The National Hemochromatosis Transplant Registry. <i>Gastroenterology</i> , 2005 , 129, 494-503	13.3	71
51	A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. <i>Gastroenterology</i> , 2005 , 129, 1198-209	13.3	219
50	Ascending multiple-dose pharmacokinetics of viramidine, a prodrug of ribavirin, in adult subjects with compensated hepatitis C infection. <i>Journal of Clinical Pharmacology</i> , 2005 , 45, 275-85	2.9	12
49	Erythropoietin is approved for the treatment of anemia associated with renal failure, chemotherapy, preoperative anemia, and human immunodeficiency virus disease. <i>Liver Transplantation</i> , 2005 , 11, 366	4.5	4
48	Clinical trial results of new therapies for HBV: implications for treatment guidelines. <i>Seminars in Liver Disease</i> , 2005 , 25 Suppl 1, 29-39	7.3	22
47	Classifying genotype F of hepatitis B virus into F1 and F2 subtypes. <i>World Journal of Gastroenterology</i> , 2005 , 11, 6295-304	5.6	26
46	Hepatitis B in liver transplant recipients as a special model of antiviral drug development. <i>Methods in Molecular Medicine</i> , 2004 , 96, 319-41		
45	Epidemiological and sequence differences between two subtypes (Ae and Aa) of hepatitis B virus genotype A. <i>Journal of General Virology</i> , 2004 , 85, 811-820	4.9	124
44	Studying the treatment of chronic hepatitis B viral infection in special populations. <i>Methods in Molecular Medicine</i> , 2004 , 96, 465-98		1
43	A case-control study for differences among hepatitis B virus infections of genotypes A (subtypes Aa and Ae) and D. <i>Hepatology</i> , 2004 , 40, 747-55	11.2	127
42	Eight genotypes (A-H) of hepatitis B virus infecting patients from San Francisco and their demographic, clinical, and virological characteristics. <i>Journal of Medical Virology</i> , 2004 , 73, 516-21	19.7	58
41	Treating hepatitis C: the state of the art. <i>Gastroenterology Clinics of North America</i> , 2004 , 33, S1-9	4.4	9
40	Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. <i>Gastroenterology</i> , 2004 , 127, 485-92	13.3	378
39	A model to predict severe HCV-related disease following liver transplantation. <i>Hepatology</i> , 2003 , 38, 34-41	11.2	171
38	De novo non-alcoholic fatty liver disease following orthotopic liver transplantation. <i>American Journal of Transplantation</i> , 2003 , 3, 1413-7	8.7	28
37	Frequent coinfection with hepatitis B virus strains of distinct genotypes detected by hybridization with type-specific probes immobilized on a solid-phase support. <i>Journal of Virological Methods</i> , 2003 , 110, 29-35	2.6	41
36	Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil. <i>Gastroenterology</i> , 2003 , 125, 107-16	13.3	190
35	Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. <i>Gastroenterology</i> , 2003 , 124, 925-32	13.3	182

34	Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. <i>American Journal of Gastroenterology</i> , 2003 , 98, 2060-3	0.7	151
33	Rate of natural disease progression in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2003 , 38, 307-14	13.4	69
32	Hepatitis B e antigen in sera from individuals infected with hepatitis B virus of genotype G. <i>Hepatology</i> , 2002 , 35, 922-9	11.2	101
31	A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. <i>Hepatology</i> , 2002 , 36, 1253-8	11.2	76
30	Elevated expression of tyrosine kinase DDR2 in primary biliary cirrhosis. <i>Autoimmunity</i> , 2002 , 35, 521-9	3	16
29	Characteristics of hepatitis B virus isolates of genotype G and their phylogenetic differences from the other six genotypes (A through F). <i>Journal of Virology</i> , 2002 , 76, 6131-7	6.6	106
28	A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. <i>Hepatology</i> , 2001 , 33, 424-32	11.2	330
27	Long-term follow-up of patients diagnosed with alcohol dependence or alcohol abuse who were evaluated for liver transplantation. <i>Liver Transplantation</i> , 2001 , 7, 581-7	4.5	70
26	Determination of hepatitis B virus genotype G by polymerase chain reaction with hemi-nested primers. <i>Journal of Virological Methods</i> , 2001 , 98, 153-9	2.6	71
25	Keratin 8 mutations in patients with cryptogenic liver disease. <i>New England Journal of Medicine</i> , 2001 , 344, 1580-7	59.2	156
24	Autoimmune liver disease. Current standards, future directions. <i>Clinics in Liver Disease</i> , 2001 , 5, 287-314	4.6	23
23	Characterization of anti-hepatitis C virus-positive sera not genotyped by restriction fragment length polymorphism or serology. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1999 , 14, 339-44	4	4
22	Future directions in the treatment of patients with chronic hepatitis C virus infection. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 1999 , 13, 57-62		7
21	Treatment of chronic hepatitis B: new antiviral therapies. <i>Current Gastroenterology Reports</i> , 1999 , 1, 20-6		4
20	Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group. <i>Hepatology</i> , 1999 , 29, 1581-6	11.2	241
19	Fetal microchimerism alone does not contribute to the induction of primary biliary cirrhosis. <i>Hepatology</i> , 1999 , 30, 833-8	11.2	98
18	Long-term follow-up after liver transplantation in patients with hepatic iron overload. <i>Liver Transplantation</i> , 1999 , 5, 369-74		37
17	Are infectious agents involved in primary biliary cirrhosis? A PCR approach. <i>Journal of Hepatology</i> , 1999 , 31, 664-71	13.4	70

16	Is there a serological difference between men and women with primary biliary cirrhosis?. <i>American Journal of Gastroenterology</i> , 1999 , 94, 2482-2486	0.7	4
15	GB virus C (GBV-C/HGV) and E2 antibodies in children preliver and postliver transplant. <i>Pediatric Research</i> , 1999 , 45, 795-8	3.2	5
14	Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. <i>Hepatology</i> , 1998 , 27, 213-22	11.2	279
13	Characterization of hepatitis G virus (GB-C virus) particles: evidence for a nucleocapsid and expression of sequences upstream of the E1 protein. <i>Journal of Virology</i> , 1998 , 72, 2738-44	6.6	49
12	Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. <i>Transplantation</i> , 1998 , 66, 956-62	1.8	72
11	Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa. <i>Hepatology</i> , 1996 , 24, 6-9	11.2	252
10	Transmission of hepatitis B virus through allotransplantation. <i>Liver Transplantation</i> , 1996 , 2, 161-4		8
9	Significance of hepatic expression of hepatitis C viral antigens in chronic hepatitis C. <i>Digestive Diseases and Sciences</i> , 1995 , 40, 2595-601	4	16
8	Recent developments in the treatment of chronic hepatitis B virus infection. <i>Expert Opinion on Investigational Drugs</i> , 1995 , 4, 95-115	5.9	4
7	Survival after liver transplantation for chronic hepatitis B using reduced immunosuppression. <i>Journal of Hepatology</i> , 1995 , 22, 257-62	13.4	30
6	Optimization for the detection of hepatitis C virus antigens in the liver. <i>Journal of Hepatology</i> , 1994 , 20, 143-7	13.4	48
5	Variation in antibody reactivity to the hepatitis C virus by comparative immunoscreening and enzyme immunoassay. <i>Viral Immunology</i> , 1993 , 6, 49-54	1.7	
4	A review of liver transplantation for the dentist and guidelines for dental management. <i>Special Care in Dentistry</i> , 1993 , 13, 74-80	1.7	12
3	Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. <i>Journal of Clinical Investigation</i> , 1991 , 88, 270-81	15.9	244
2	Calcium compartmentation and exchange rates in primary hepatocyte culture. <i>Analytical Biochemistry</i> , 1990 , 187, 187-96	3.1	3
1	Chronic Hepatitis B Viral Infection 2112-2138		1